IPO listing forecast: GMP hints at muted start for Anlon Healthcare shares

Anlon Healthcare shares garnered decent demand, being oversubscribed by 7.13 times

Anlon Healthcares IPO
SI Reporter New Delhi
3 min read Last Updated : Sep 02 2025 | 3:15 PM IST
Anlon Healthcare IPO listing forecast: The grey market trends suggest a subdued listing for the chemical manufacturing company Anlon Healthcare, which is slated to debut on Wednesday, September 3, 2025. The company has raised ₹121 crore by offering an entirely fresh issue of 13.3 million equity shares.  The public issue garnered decent demand, being oversubscribed by 7.13 times. The demand was driven by retail investors, who oversubscribed the category reserved for them by 47.30 times, according to data from the NSE.
 
The basis of allotment for Anlon Healthcares IPO shares was finalised on Monday, September 1, 2025. Now, investors are awaiting the listing of the company’s shares on the stock exchanges. Before the official listing, the unlisted shares of Anlon Healthcare were trading at ₹93 per share, reflecting a grey market premium (GMP) of ₹2 to ₹2.20 per share over the issue price of ₹91, according to the sources tracking the unofficial market activities.   If current grey market trends hold, Anlon Healthcare shares may list at around ₹93 per share, yielding a return of over 2 per cent for investors who were allotted shares during the IPO. That said, since the grey market is unregulated, investors should not rely solely on the GMP (Grey Market Premium) to predict listing performance.

Anlon Healthcare IPO details

The Anlon Healthcare IPO consisted of 13.3 million equity shares worth ₹121.03 crore, offered at a price band of ₹86-91 per share, with a lot size of 164 shares. The public issue was open for subscription from August 26 to August 29, 2025. KFin Technologies serves as the registrar for the public issue, while Interactive Financial Services is the sole book running lead manager.
 
The company intends to use the proceeds from the public issue for several purposes. These include funding capital expenditure requirements for expansion, repaying or prepaying certain outstanding secured borrowings (term loans), meeting working capital needs, and covering general corporate expenses.

About Anlon Healthcare

Anlon Healthcare is a chemical manufacturing company that specializes in the production of high-purity advanced pharmaceutical intermediates (Pharma Intermediates) and active pharmaceutical ingredients (APIs). Pharma intermediates serve as raw materials or key starting materials in the manufacturing of APIs. Anlon Healthcare’s APIs are used as raw materials for pharmaceutical formulations, including various types of Finished Dosage Forms (FDF) such as tablets, capsules, ointments, and syrups. These APIs are also incorporated into nutraceutical formulations, personal care products, and animal health products.
 
Anlon Healthcare's product range spans pharmaceutical intermediates, APIs, nutraceutical APIs, and ingredients for personal care and veterinary applications. The company manufactures its active pharmaceutical ingredient products in accordance with both Indian and international pharmacopeia standards, including IP, BP, EP, JP, and USP.
 
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :IPO listing timeIPO GMPIPO REVIEWinitial public offerings IPOsIPO market

First Published: Sep 02 2025 | 3:15 PM IST

Next Story